Form 4: Generation Bio CSO Converts Restricted Stock Units, Adjusts Holdings for Tax

Generation Bio Co.'s Chief Scientific Officer, Phillip Samayoa, converted 1,147 restricted stock units into common stock and subsequently disposed of 337 shares for tax purposes, resulting in a net increase of 810 directly held common shares.

Summary

• Phillip Samayoa, Chief Scientific Officer of Generation Bio Co. (GBIO), reported transactions on July 15, 2025.
• Samayoa acquired 1,147 shares of common stock through the conversion of restricted stock units.
• Following this acquisition, Samayoa's direct beneficial ownership of common stock was 140,925 shares.
• Concurrently, Samayoa disposed of 337 shares of common stock at a price of $0.426 per share to cover tax liabilities related to the vesting.
• After these transactions, Samayoa's direct beneficial ownership of common stock stands at 140,588 shares.
• The reported common stock holdings include 11,259 shares acquired through the company's employee stock purchase plan since April 15, 2025.
• Samayoa still holds 6,876 restricted stock units.
• The restricted stock units converted were part of a grant of 18,345 units on January 20, 2023, vesting over four years with quarterly installments after an initial 25% vested on January 15, 2024.

Sentiment

Score: 6

Explanation: The sentiment is slightly positive as it reflects the vesting of equity compensation, indicating continued alignment of executive interests with shareholders. The disposition of shares is for tax purposes, which is a routine and expected event, not indicative of negative sentiment towards the company.

Positives

• Conversion of 1,147 restricted stock units into common stock, increasing direct share ownership.
• Continued vesting of previously granted restricted stock units, indicating ongoing employee retention and long-term incentive alignment.
• Acquisition of 11,259 shares through the employee stock purchase plan since April 15, 2025, demonstrating ongoing investment by the Chief Scientific Officer.

Negatives

• Disposition of 337 shares of common stock at $0.426 per share to satisfy tax withholding obligations, reducing the total number of shares held directly.

Future Outlook

NA

Industry Context

This filing is a routine insider transaction report, common across all industries for publicly traded companies when executives' equity compensation vests or is exercised. It does not provide specific industry context.

Comparison to Industry Standards

• This is a standard Form 4 filing for an insider transaction (vesting and tax-related sale).
• The transaction type and reporting are consistent with typical corporate governance and compensation practices for executives in publicly traded companies, including those in the biotechnology sector like Generation Bio Co.
• No specific comparable companies, projects, or results are mentioned in the document to assess against.

Stakeholder Impact

• Shareholders: Minor dilution from the vesting of RSUs, but also a sign of continued executive alignment through equity ownership. The tax-related sale is a common occurrence and not indicative of a change in investment thesis.
• Employees: Reflects the standard operation of the company's equity compensation plan, which is a common benefit for employees.

Key Dates

Keywords

Generation Bio Co., GBIO, Phillip Samayoa, Chief Scientific Officer, SEC Form 4, Insider Trading, Stock Ownership, Restricted Stock Units, RSU Conversion, Employee Stock Purchase Plan, Tax Withholding, Equity Compensation